Viatris, Inc. (VTRS)
| Market Cap | 17.02B |
| Revenue (ttm) | 11.95B |
| Net Income (ttm) | -669.90M |
| Shares Out | 1.21B |
| EPS (ttm) | -1.11 |
| PE Ratio | n/a |
| Forward PE | 4.03 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $14.08 |
| Previous Close | $13.93 |
| Change ($) | 0.15 |
| Change (%) | 1.08% |
| Day's Open | 13.82 |
| Day's Range | 13.78 - 14.10 |
| Day's Volume | 12,729,327 |
| 52-Week Range | 12.94 - 18.86 |
It depends on what type of investor you are.
Both income investors and value investors will probably like these stocks.
PITTSBURGH, May 6, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a new kind of healthcare company formed in November 2020, today released its inaugural sustainability report, reinforcing its strong ...
Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q1 results.
Selecting stocks whose market capitalization surpasses $10 billion and whose price-book ratios are below 1.5 could provide value investors with a higher likelihood to find opportunities amid U.S.-listed...
PITTSBURGH, April 30, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference ...
PITTSBURGH, April 29, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the BofA Securities 2021 Health Care Conference on Tuesday...
But that's not the best reason to consider buying it.
These great companies can kick-start or further your journey toward financial freedom.
Bear of the Day: Viatris (VTRS)
On the hunt for bargains in today's overvalued market? Look no further.
These companies are big-time bargains in the eyes of professional investors.
PITTSBURGH, April 12, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its first quarter 2021 financial results on Monday, May 10, before the open of the U.S. financial markets. The com...
Look at more than just the valuation metrics.
The stock of Viatris (NAS:VTRS, 30-year Financials) appears to be modestly undervalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the st...
Income-seeking investors will love these stocks with great dividends and attractive valuations.
It's been a rough start for the combined generic drug company.
PITTSBURGH and ST. PAUL, Minn., March 8, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery L.P. today announced that the U.S. Food and Drug Administration (FDA) granted tentativ...
PITTSBURGH, March 4, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the Barclays Global Healthcare Conference on Wednesday Marc...
PITTSBURGH, March 1, 2021 /PRNewswire/ -- At a virtual meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS) will outline how the company expects to lead as a new kind of healthcare c...
Davis Select Advisors recently released its fourth-quarter 2020 portfolio update. Among the changes made during the quarter, the firm disclosed a new position in Viatris Inc. (NASDAQ:VTRS), a position b...
Viatris (VTRS) declines after it announces outlook for 2021 and reaffirms strategic commitments.
The company released its guidance for its fiscal year 2021.
If people need Xanax in the future -- and they definitely will -- they'll need Viatris to make it.
PITTSBURGH, Feb. 9, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that it will host a conference call at 8 a.m. ET on Monday, Feb. 22 to discuss 2021 financial guidance. The briefing ...
Covid-19 vaccines are getting all the glory after multi-bagger returns last year but these seven pharmaceutical stocks have a strong future ahead. The post 7 Pharmaceutical Stocks With Compelling Pipeli...
Many investors appear to be overlooking the potential for this brand-new stock.
High dividend yields plus low valuations could be just the ticket for income-seeking investors.
I received shares in Viatris following the spin-off from Pfizer. The company will only start paying a dividend next year.
It's no bull: These stocks are set to weather a potential storm.
All three also offer attractive dividends.
Whether or not you believe that Viatris can make you rich depends on how strongly you believe in biosimilars.
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...
PITTSBURGH, Dec. 18, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the lawsuit bro...
PITTSBURGH, Dec. 15, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation ("TRC") to purchase up to 6,000,000 shares, or ap...
Viatris (VTRS) announces job cuts as part of additional details of its previously disclosed multi-year global restructuring initiative.
Shares of Viatris Inc. were down 0.2% in premarket trading on Friday after the company said it plans to close or divest up to 15 manufacturing sites and may cut up to 9,000 jobs, or 20% of its workforce...
PITTSBURGH, Dec. 11, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced additional details of its previously disclosed multi-year global restructuring initiative. The restructuring initiat...
About VTRS
Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agen... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | |
| Stock Exchange NASDAQ | Ticker Symbol VTRS |
Analyst Forecasts
The average 12-month stock price forecast for Viatris is 20.07, which is an increase of 42.54% from the latest price.